
Tesamorelin vs Sermorelin: Mechanisms, Efficacy, Dosing, Safety, and Cost
Tesamorelin is an FDA‑approved growth‑hormone–releasing factor (GHRF) analog indicated to reduce excess abdominal fat in adults with HIV‑associated lipodystrophy and is not indicated for weight loss in the general population; its current U.S. labeling also includes dosing and safety monitoring guidance. See the EGRIFTA SV Prescribing Information for full details. Sermorelin (GHRH 1–29) previously held approvals for pediatric GH diagnostics/therapy but was discontinued by the sponsor; the FDA determined these products were not withdrawn for reasons of safety or effectiveness, and today access is typically via compounding rather than an approved brand. See the Federal Register determination for context.













